Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Zentalis Pharmaceuticals Inc ZNTL

Biotechnology
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ZNTL)

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

GlobeNewswire 7 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 3, 2025

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

GlobeNewswire March 3, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

ACCESS Newswire March 1, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

ACCESS Newswire February 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

PR Newswire February 25, 2025

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire February 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

ACCESS Newswire February 23, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

ACCESS Newswire February 21, 2025
View More News ››

Opinion & Analysis (NDAQ:ZNTL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL): A Promising On

http://beyondspx.com/2024/08/01/zentalis-pharmaceuticals-inc-nasdaqzntl-a-promising-oncology-pipeline-backed-by-robust-financials/
MikeTester - August 1, 2024

Neutral Recommendation Issued On ZNTL By UBS

Breaking News: $ZNTL Neutral Recommendation Issued On ZNTL By UBS2024-06-20 08:30:04 ET UBS analyst issues NEUTRAL recommendation for...
whytestocks - June 20, 2024

Equal-Weight Recommendation Issued On ZNTL By Morgan Stanley

News; $ZNTL Equal-Weight Recommendation Issued On ZNTL By Morgan Stanley2024-06-18 14:30:04 ET Morgan Stanley analyst issues EQUAL...
whytestocks - June 18, 2024

ZNTL Price Target Alert: $4.00. Issued by Wedbush

NEWS: $ZNTL ZNTL Price Target Alert: $4.00. Issued by Wedbush2024-06-18 12:00:05 ET Robert Driscoll from Wedbush issued a price target...
whytestocks - June 18, 2024

Equal-Weight Recommendation Issued On ZNTL By Wells Fargo

JUST IN: $ZNTL Equal-Weight Recommendation Issued On ZNTL By Wells Fargo2024-06-18 11:15:05 ET Wells Fargo analyst issues EQUAL-WEIGHT...
whytestocks - June 18, 2024

Zentalis Pharmaceuticals to Participate in Upcoming Investor

JUST IN: $ZNTL Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences | BenzingaNEW YORK and SAN DIEGO, Feb. 28, 2024 ...
whytestocks - February 28, 2024
View more Bullboard ››

Vista Gold Corp.

Vista Gold Corp.

Vista Gold Corp. (NYSE American and TSX: VGZ) holds the Mt Todd gold project, a shovel-ready development-stage deposit ...
View More »